As the activation of TGF‐β signaling that accompanies gliomagenesis (yet another GBM feature shared with BC) might account for this observation, TGF‐β‐targeting strategies may also need to be incorporated in combinatorial regimens to unlock the efficacy of RT and ICIs in patients with GBM. The gene discussed is TGFB1; the disease is breast cancer.